Anticoagulation in Atrial Fibrillation with Advanced Chronic Kidney Disease

Introduction to Anticoagulant Options

Apixaban has the lowest renal clearance (25%) among direct oral anticoagulants (DOACs), making it more suitable for patients with impaired renal function, according to the European Heart Journal 1, 2
The American College of Cardiology recommends apixaban as a first-line treatment option for patients with atrial fibrillation and advanced chronic kidney disease, due to its lower risk of major bleeding 3, 4

Warfarin use in CKD patients is associated with increased bleeding risk, especially during therapy initiation, as reported in the European Heart Journal 1
Warfarin may increase vascular calcification and calcific uremic arteriopathy in advanced CKD, according to the Journal of the American College of Cardiology 3, 4
Dabigatran has the highest renal clearance (80%) among DOACs, increasing bleeding risk in advanced CKD, as noted in the European Heart Journal 1, 2
Rivaroxaban has moderate renal clearance (35%) and requires dose adjustment to 15 mg daily for patients with CrCl 30-49 mL/min, as stated in the European Heart Journal 1, 2

Apixaban dose should be reduced to 2.5 mg twice daily if the patient meets at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, according to the European Heart Journal 1
Regular monitoring of renal function is essential for all patients on anticoagulants, especially those with CKD, as recommended by the European Heart Journal 1

The 2019 AHA/ACC/HRS guideline provides a soft recommendation for using either warfarin or apixaban in advanced CKD patients with atrial fibrillation, as stated in the Journal of the American College of Cardiology 3, 4
The American Heart Association, American College of Cardiology, and Heart Rhythm Society suggest considering left atrial appendage occlusion as an alternative to anticoagulation if bleeding risk is prohibitive, according to the Journal of the American College of Cardiology 3